Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
View Patent ↗Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
1. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising subcutaneously administering to the subject in need thereof a therapeutically effective amount of exendin(9-39);
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39);
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml; and
wherein the subject exhibits one or more of Whipple's triad, the occurrence of capillary glucose ≤50 mg/dL at least once per month, and a plasma glucose concentration of ≤60 mg/dL during a tolerance test.
2. The method of claim 1 , wherein the tolerance test is an oral glucose tolerance test or a meal tolerance test.
3. The method of claim 1 , wherein the subject exhibits a plasma glucose concentration of ≤55 mg/dL and plasma insulin ≥3 uU/mL during the tolerance test, or wherein the subject exhibits a plasma glucose concentration of ≤55 mg/dL and c-peptide >0.3 mg/dL during the tolerance test.
4. The method of claim 1 , wherein the therapeutically effective amount is 10-20 mg of exendin(9-39).
5. The method of claim 1 , wherein the exendin(9-39) is administered once per day.
6. The method of claim 1 , wherein the exendin(9-39) is administered twice per day.
7. The method of claim 1 , wherein the subject has previously had bariatric surgery.
8. The method of claim 7 , wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.
9. The method of claim 1 , wherein the subject has previously had gastrointestinal surgery.
10. The method of claim 9 , wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.
11. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising subcutaneously administering to the subject in need thereof a therapeutically effective amount of exendin(9-39),
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39);
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml; and
wherein the subject is prediabetic and/or insulin resistant.
12. The method of claim 11 , wherein the subject has a congenital, acquired, or induced form of hyperinsulinemic hypoglycemia.
13. The method of claim 11 , wherein the therapeutically effective amount is 10-20 mg of exendin(9-39).
14. The method of claim 11 , wherein the exendin(9-39) is administered once per day.
15. The method of claim 11 , wherein the exendin(9-39) is administered twice per day.
16. The method of claim 11 , wherein the subject has previously had bariatric surgery.
17. The method of claim 16 , wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.
18. The method of claim 11 , wherein the subject has previously had gastrointestinal surgery.
19. The method of claim 18 , wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.
20. A method for treating hyperinsulinemic hypoglycemia in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of exendin(9-39) twice-per-day (BID);
wherein the therapeutically effective amount is 2-100 mg of exendin(9-39);
wherein the exendin(9-39) is administered at a concentration of 20-45 mg/ml; and
wherein the second daily dose is administered 7 to 15 hours after the first daily dose.
21. The method of claim 20 , wherein the therapeutically effective amount is 10-20 mg of exendin(9-39).
22. The method of claim 20 , wherein the subject has previously had bariatric surgery.
23. The method of claim 22 , wherein the bariatric surgery is Roux-en-Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of the duodenum, vagal nerve blockade, or pyloroplasty.
24. The method of claim 20 , wherein the subject has previously had gastrointestinal surgery.
25. The method of claim 24 , wherein the gastrointestinal surgery is gastrectomy, Nissen Fundoplication, or esophagectomy.